How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH by Lee, Shen-Han & Griffiths, John R.
  
Cancers 2020, 12, 1616; doi:10.3390/cancers12061616 www.mdpi.com/journal/cancers 
Review 
How and Why Are Cancers Acidic? Carbonic 
Anhydrase IX and the Homeostatic Control of 
Tumour Extracellular pH 
Shen-Han Lee 1,* and John R. Griffiths 2 
1 Department of Otorhinolaryngology, Hospital Sultanah Bahiyah, Jalan Langgar,  
Alor Setar 05460, Kedah, Malaysia 
2 Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, 
Cambridge CB2 0RE, UK; john.griffiths@cruk.cam.ac.uk 
* Correspondence: shen-han.lee@cantab.net 
Received: 17 May 2020; Accepted: 15 June 2020; Published: 18 June 2020 
Abstract: The acidic tumour microenvironment is now recognized as a tumour phenotype that 
drives cancer somatic evolution and disease progression, causing cancer cells to become more 
invasive and to metastasise. This property of solid tumours reflects a complex interplay between 
cellular carbon metabolism and acid removal that is mediated by cell membrane carbonic 
anhydrases and various transport proteins, interstitial fluid buffering, and abnormal tumour-
associated vessels. In the past two decades, a convergence of advances in the experimental and 
mathematical modelling of human cancers, as well as non-invasive pH-imaging techniques, has 
yielded new insights into the physiological mechanisms that govern tumour extracellular pH (pHe). 
In this review, we examine the mechanisms by which solid tumours maintain a low pHe, with a 
focus on carbonic anhydrase IX (CAIX), a cancer-associated cell surface enzyme. We also review the 
accumulating evidence that suggest a role for CAIX as a biological pH-stat by which solid tumours 
stabilize their pHe. Finally, we highlight the prospects for the clinical translation of CAIX-targeted 
therapies in oncology. 
Keywords: cancer microenvironment; tumour pH; carbonic anhydrase IX; cancer metabolism; pH-
stat; pH measurement in vivo; magnetic resonance spectroscopy; models of tumour pH regulation 
 
1. Introduction 
The pH of extracellular fluid (pHe) in healthy tissues is tightly regulated between 7.35 and 7.45, 
in order to sustain normal physiology and cellular metabolism. In contrast, the pHe of cancers is 
acidic, between 6.3 and 7.0, reflecting the dysregulation of the acid-base homeostatic mechanisms 
that operate within solid tumours. 
Almost a century ago, Otto Warburg published his seminal observation, termed aerobic 
glycolysis, in which tumour slices metabolized glucose into lactic acid instead of CO2, even in the 
presence of oxygen [1]. This observation, now termed ‘The Warburg Effect’ gave rise to the erroneous 
assumption that lactic acid produced by cancer cells would tend to acidify their cytoplasm and thus 
lower their intracellular (pHi) [2,3]. Microelectrode studies on solid tumours appeared to support the 
assertion that tumours were acidic, and for half a century it was believed that both their pHi and their 
pHe were acidic. That dogma was overturned by the first magnetic resonance spectroscopy (MRS) 
studies on cancer in the early 1980s [4–6], which demonstrated that the pHi of solid tumours, both in 
animal models and in patients, was usually on the alkaline side of neutrality, much like that of normal 
cells. Subsequent MRS studies using extracellular pH probes, such as 3-aminopropylphosphonate (3-
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APP) [7] and the imidazole probes 2-imidazole-1-yl-3-ethoxycarbonyl propionic acid (IEPA) [8] and 
(±)2-(imidazol-1-yl) succinic acid (ISUCA) [9], firmly established the conclusion that it was the 
extracellular, interstitial space of tumours that was acidic, with typical pHe values of 6.3–7.0. 
In the last two decades, the acidic tumour microenvironment has become recognized as a feature 
of the tumour phenotype that drives the progression of cancer. It modulates several steps along the 
spectrum from preneoplasia to neoplasia, and then along the invasion–metastasis cascade, thus 
conferring an evolutionary advantage on solid tumours. Several reviews have discussed aspects of 
this process [10–12]. In parallel, advances in imaging technology, biophysics and chemistry have 
converged with the progress in experimental modelling of human cancers to yield novel insights into 
the mechanisms that cause and regulate the acidic tumour pHe; the enzyme carbonic anhydrase IX 
(CAIX) has been found to play a key role in these mechanisms. From a clinical perspective, the acidic 
tumour pHe is also an emerging diagnostic and therapeutic target. While current targeted therapies 
in oncology mostly focus on precise molecular targets such as receptor tyrosine kinases [13,14], 
microRNAs [15,16], or the ubiquitin–proteasome pathway [17,18], the acidic tumour pHe is an 
attractive target because it is a common phenotype that is found across a wide spectrum of cancers. 
In this review, we will discuss the common imaging techniques and their applications in various 
experimental models of cancer. We will also highlight the experimental findings that inform how 
CAIX regulates tumour pHe, and discuss the implications of these findings concerning the 
pathophysiology of disease progression. 
2. Methods for Measuring Tumour pH 
Techniques for measuring pH in living systems are central to the study of tumour pHe. They 
have been extensively reviewed elsewhere [19,20]; however, we will briefly introduce some of the 
major techniques to facilitate our subsequent discussion concerning their applications in cancer 
models. 
The first measurements of tissue pH in vivo used microelectrodes, which measure the potential 
differences of solutions with differing proton concentrations across a thin glass membrane. The 
electrodes used in living tissues are much larger than cells, so they mainly measure pHe. The principle 
disadvantage of microelectrode pH measurement is that it is invasive and causes damage to cells. 
Today, many non-invasive imaging modalities have been developed to measure tissue pH, 
including magnetic resonance, fluorescence imaging, positron emission tomography (PET) and 
single-photon emission computerized tomography (SPECT). They rely on a variety of mechanisms 
to generate image contrast, and have a wide range of spatial resolution. While these techniques have 
been useful in the preclinical setting, none of them have entered routine medical use, although efforts 
are underway to translate some of them into the clinic. Table 1 summarizes the range of non-invasive 
or minimally invasive techniques available for measuring tissue pHe. 
Table 1. Summary of the non-invasive techniques for measuring tissue pH. 
Imaging Technique Description 
Fluorescence 
imaging 
Various fluorescent dyes and proteins exhibit a wavelength shift upon protonation. 
Ratiometric measurement of the fluorescent output at each wavelength allows the 
calculation of pH.  
Advantage: very high spatial resolution (<1 µm) enables the measurement of 
subcellular pH gradients 
Disadvantage: low penetration of the tissue limits its use in whole animal and 
clinical imaging. 
The use of SNARF-1 fluorescent dye on tumours grown in dorsal window chamber 
models has enabled the in vivo imaging of tumour pH [21,22]. 
Magnetic resonance 
spectroscopy 
MRS measures the pH-dependent chemical shift of MRS-visible nuclei such as 1H, 
31P, and 19F in endogenous or exogenous compounds. 
In compounds with pKa close to the physiological range, this property can be 
exploited to measure pH by comparing the chemical shift of the pH-sensitive peak 
with a previously constructed titration curve of chemical shift vs. pH. 
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31P MRS can be used to measure pHi from the chemical shift of endogenous 
inorganic phosphate, while pHe can be measured with the use of 3-
aminopropylphosphonate (3-APP). However, because of the low sensitivity of the 
31P nucleus, this technique has poor spatial resolution, and cannot be used to 
generate pHe maps [7,23,24]. 
19F MRS can be used to measure pHe with ZK-150471 (3-[N-(4-fluoro-2-
trifluoromethylphenyl)-sulfamoyl]-propionic acid) and fluorinated vitamin B6 
derivatives (6-fluoropyriodoxol & 6-fluoropyridoxamine) [25]. 
1H magnetic resonance spectroscopic imaging (MRSI) of the imidazole-containing 
compounds, (±)2-(imidazol-1-yl)3-ethoxycarbonylpropionic acid (IEPA) [8] and 
(±)2-(imidazol-1-yl) succinic acid (ISUCA) [9] can be used to generate pHe maps 
with a spatial resolution of 1–2 mm. However, the poor temporal resolution of 10–
30 min precludes measurement of pH changes. 
Hyperpolarised 
(HP) 13C MR 
imaging 
Dissolution dynamic nuclear polarization (d-DNP) results in a substantial increase 
in the magnetic resonance (MR) signal [26], allowing measurements of spatial and 
temporal changes in pHe from exogenously administered hyperpolarized 
molecules. 
Tumour pHe can be measured with hyperpolarized H13CO3− using the ratio of the 
peak intensities of H13CO3−and 13CO2 [27]. 
However, this technique is dependent on carbonic anhydrase activity, and in 
tissues with low carbonic anhydrase activity, the measured pH will tend to be 
overestimated [28]. 
pHi can be quantified from HP 13CO2 produced from [1-13C] pyruvate in organs with 
a high pyruvate dehydrogenase flux, e.g., the heart [29]. The short T1 of [13C] 
bicarbonate limits spatial resolution [27]. The current resolution of 2–10 mm is 
coarser than that of some other MR imaging approaches. 
Other 13C-labelled compounds have been shown to be able to measure in vivo pHe 
using HP 13C MRS: N-(2-acetamido)-2-aminoethanesulfonic acid (ACES) [30], 
diethylmalonic acid (DEMA) [31], zymonic acid [32], and amino acid derivatives 
[33].  
Chemical exchange 
saturation transfer 
(CEST) 
CEST measures pHe from the relative rates of protonation and deprotonation of 
amide functional groups on either endogenous molecules or administered contrast 
agents. It has the advantage of high spatial resolution (0.1–2 mm) but has low 
sensitivity. 
AcidoCEST is a CEST-based method of measuring pHe based on exogenous 
contrast agent administration [34].  
Iopidamol, a United States Drug and Food Agency (FDA)-approved contrast agent, 
has been used with this approach to measure pHe in metastatic ovarian cancer 
tumour models [35]. 
MR relaxometry 
pH is measured from paramagnetic contrast agents with a pH-dependent change in 
T1 relaxation time. It has the advantage of high signal-to-noise ratio and spatial 
resolution (0.2–2 mm). However, to accurately measure the pH, this technique 
requires the administration of a second pH-insensitive agent to correct the 
concentration of the pH-sensitive agent.  
An example of the agent is GdDOTA-4AmP5−, a pH-dependent chelate which has 
been used together with a pH-independent analogue, GdDOTP5−, to generate high 
spatial resolution maps of tissue pHe in a rat glioma model [36]. 
PET/SPECT imaging 
In vivo pHe imaging using positron emission tomography (PET) has been achieved 
using 11C-dimethyloxazolidinedione (DMO) [37], 11CO2 [38], and 123I-labeled 
derivatives of malonic acid [39]. 
pH (low) insertion peptides (pHLIP) is a class of acid-targeting peptides that are 
activated to insert across the membrane of cancer cells by the acidity at the cell 
surface. These peptides can be conjugated with 64Cu to target the radioisotope to 
regions where the pHe is below 7.0 [40].  
Caged derivatives of 18F-fluorodeoxyglucose (FDG) can be localized to tumours by 
the release of the caging group in low pHe, followed by uptake via glucose 
transporters [41]. 
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PET-based techniques are readily implemented with good spatial resolution (1–2 
mm). A limitation of this approach is that it cannot measure absolute pH, and only 
indicates regions below a certain pHe threshold. pH values can be estimated from 
arterial blood sampling and model fitting, but these values have not been correlated 
with microelectrode measurements. 
3. Experimental Cancer Models for the Study of Tumour pH Regulation 
To gain insight into tumour pHe regulation in vivo, imaging techniques have to be deployed on 
cancer models ranging from traditional monolayer cell cultures to mouse models and human 
patients. The measurement of tumour pHe becomes more challenging as the complexity and 
physiologic relevance of the model system increase. 
Two-dimensional (2D) monolayer cell cultures have traditionally been the workhorse of cancer 
research, and most early studies on cancer pH regulation were done in this system. However, the 
extracellular environment within the monolayer cultures does not reflect the tumour 
microenvironment in vivo, not least because H+, CO2 and HCO3− can freely diffuse between the cells 
and the relatively huge volume of culture medium [42,43]. In contrast, the cancer cells in solid 
tumours co-exist in a disorganized tissue architecture with stromal fibroblast cells and various 
immune cells, all of which derive their blood supply from an abnormal tumour-associated 
vasculature [44]. The restricted diffusive capacity of H+, CO2 and HCO3− in the extracellular space of 
solid tumours [45] causes spatiotemporal heterogeneity of oxygenation and cellular metabolism, 
resulting in gradients of pHe that will not occur in 2D cell cultures. 
In vitro 3D cell spheroid systems simulate some aspects of the spatial architecture and cell-to-
cell contact found in solid tumours in vivo and provide a tractable platform to study the role of 
several cell physiological processes in regulating the tumour microenvironmental pH [43]. Spheroids 
are cell cultures in which cells are grown in clusters or aggregates, typically without the addition of 
the extracellular matrix or growth factors to the culture medium, or by growing cell clusters in low-
attachment culture plates. Optical imaging by pH-sensitive fluorescent dyes can be used to measure 
spatial gradients of pHi and pHe in these spheroid models. 
More recently, the application of organoid technology from the field of stem cell research has 
led to the development of cancer organoids—microscopic self-organizing, 3D structures that 
recapitulate many of the structural and functional aspects of tumours in vivo [46]. The cancer cells 
are embedded in a 3D matrix such as a collagen or basement membrane, sometimes with the addition 
of growth factors that promote growth as a 3D structure. Such organoids can also be co-cultured with 
fibroblasts and immune cells, thus recreating something of the cellular heterogeneity found within 
solid tumours. These organoids are increasingly used in the study of tumour metabolism and pH 
regulation, and they present an improvement over tumour spheroids in modelling in vivo tumour 
physiology [47,48]. 
However, tumour pH regulation cannot be fully modelled in culture, even by using tumour 
spheroids and organoids. Cancer cells in solid tumours are genetically heterogeneous, and they co-
exist with non-transformed stromal and immune cells within an unknown nutrient and O2 milieu, 
with further differences due to tumour stage and exposure to therapy. While in situ tumours within 
patients remain the gold standard for studying tumour pHe, animal models allow studies of gene and 
protein function by analysing the phenotypes that arise after silencing or overexpressing particular 
genes. Animal models for studying cancer biology differ in their complexity and their degree of 
fidelity to human cancers [49]. They include genetically engineered mouse models (GEMMs) that 
develop tumours in situ, as well as allograft models and xenograft models derived from human 
tumours (patient-derived xenografts) or cancer cell lines. These in vivo models come closer to the 
physiological complexity of human cancers than cell culture preparations, and they also allow 
interactions between the tumour and normal host tissues. Nonetheless, the interpretation of the data 
from mouse models must have the caveat that factors such as diet, strain, sex, age, husbandry and 
environmental stressors can affect metabolism of the host animal, and thus the metabolism of the 
tumour [50,51]. Moreover, pH regulation studies in such model systems are restricted by the 
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currently available imaging techniques, which have limited sensitivity, reproducibility and 
spatiotemporal resolution, and face challenges with the targeting and accessibility of pH probes. 
4. Why is Tumour pHe Acidic? 
For many years, it was believed that the increased lactate metabolic flux and extrusion of this 
acidic metabolite from cancer cells explained tumour extracellular acidification. This simple model 
assumed that lactic acid exported from cancer cells into the interstitial fluid accumulates because it 
cannot be transported away rapidly enough to the blood vasculature, and that acidification ensues 
because of the poor buffering capacity of the extracellular fluid. 
Early evidence to challenge this concept came from a series of studies by Tannock and colleagues 
in the 1990s, which found that tumours derived from glycolysis-deficient Chinese Hamster 
fibroblasts, that lacked both the phosphoglucose isomerase enzyme and a number of glucose 
transporters, surprisingly had an acidic pHe in vivo, even though negligible amounts of lactic acid 
were formed and these cells were not able to acidify the culture media in vitro [52]. This finding was 
replicated using Chinese Hamster ovary cells lacking lactate dehydrogenase, which also showed 
minimal lactic acid production in vitro but were nonetheless capable of producing tumours with 
acidic pHe when transplanted in vivo [53]. One possible explanation for this unexpected result would 
be that these mutant cells produced large amounts of CO2 by oxidative metabolism. In fact, earlier 
studies by Gullino et al., sampling interstitial fluid from solid tumours grown in ‘Gullino’ PTFE 
chambers, showed that the tumour interstitial fluid of numerous tumour types contained high levels 
of CO2 [54]. 
Numerous studies on cancer metabolism over the past decade have revealed that cancer cells 
exhibit aerobic glycolysis due to the activation of oncogenes, the loss of tumour suppressor genes, 
and the upregulation of the PI3K pathway, and that one advantage of these high glycolytic rates is 
the availability of precursors for anabolic pathways, that are needed for the biosynthesis of cellular 
building blocks during proliferation [55,56]. While this Warburg effect has been observed in many 
human cancers (and is indeed the basis by which FDG-PET scans operate), studies have 
demonstrated that human cancers show distinct metabolic heterogeneity [57] and produce most of 
their metabolic energy through glucose oxidation via the tricarboxylic acid cycle, resulting in the 
formation of CO2 [58–60]. 
By sampling the blood entering and exiting solid tumours in vivo, it is possible to calculate their 
outputs of lactic acid and of CO2. Such calculations have been performed on both animal models and 
tumours in patients, and they have found that the tumour CO2 output is comparable to or greater 
than that of lactate. Kallinowksi et al. studied a tumour xenograft model in which human tumour 
xenografts were grown in nude rats, on pedicles containing the epigastric artery and vein, and were 
prevented from acquiring other vasculature by polyethylene sheaths [61,62]. This defined blood 
supply allowed measurement of the blood flow and assay of metabolite concentrations from the 
artery supplying and the veins draining the tumour. Holm et al. performed similar balance studies 
on human colon carcinomas during bowel resection surgery, by cannulating the mesenteric vessels 
supplying these tumours and measuring the metabolites in blood from the mesenteric artery and vein 
[63]. Calculations of the production of CO2 from the substrate balance data reported by Kallinowski 
et al. found that human xenografts in nude rats produced 588–850 nmol/g/min CO2 vs. 
527 nmol/g/min lactate, and similar calculations from the data in Holm et al. found that colonic 
tumours in human patients produced five times more CO2 than lactate, 1296 nmol/g/min CO2 vs. 
220 nmol/g/min lactate [64]. These balance studies suggested that solid tumours in vivo synthesised 
most of their ATP by oxidative metabolism (because the complete oxidation of glucose to CO2 
phosphorylates 16 times the amount of ATP obtained from glycolysis to lactate [65]), and they did 
not support the dogma that cancer cells rely on aerobic glycolysis for their energetic requirements or 
that tumour extracellular acidification is entirely due to lactate extrusion. 
However, although these in vivo studies suggest that CO2 will be a significant source of 
metabolic acid production in cancer cells, the higher pK of carbonic acid (pKa 6.35) compared to that 
of lactic acid (pKa 3.86) means that, on a mole for mole basis, CO2 would have a much smaller 
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acidifying effect than lactic acid. This suggests that in order for CO2 to be a significant source of 
acidity in the tumour extracellular space, there must be an additional mechanism in play, such as one 
to accelerate the hydration of CO2 to form H+. In the next section of this review, we explore how CAIX 
provides such an additional mechanism and thus maximises the locally acidifying effect of CO2 
production. 
5. Carbonic Anhydrase IX and Its Role in Cancer Biology 
The role of the enzyme CAIX is central to understanding how CO2 production leads to the 
acidification of the tumour interstitial space. CAIX belongs to a family of zinc metalloprotein enzymes 
that catalyse the reversible interconversion of CO2 to form HCO3− and H+ [66]. In mammals, there are 
16 isoforms of carbonic anhydrases, which differ in their activity and cellular localization [67]. Cancer 
cells primarily express the plasma membrane-associated carbonic anhydrases, CAIX and CAXII [68–
70], as well as intracellular carbonic anhydrases such as CAI [71,72] and CAII [73–75]. CAIX has been 
extensively studied as a potential therapeutic target in oncology, owing to its specificity to cancer 
cells—it has a very restricted expression in the normal stomach and gut epithelial cells [76] but is 
strongly upregulated in many different types of tumour tissue [77]. Several preclinical studies have 
suggested that the inhibition of the CAIX function delays the growth of tumours [78–80] and reduces 
invasion and metastasis under experimental conditions [79]. 
CAIX is a protein that is tethered to the cell surface membrane. It is comprised of an 
extracellularly facing catalytic domain, an N-terminal proteoglycan-like (PG) domain, a single 
transmembrane domain and a short intracellular C-terminal tail [70]. The N-terminal PG domain is 
unique to CAIX within the CA family [81] and has been shown to be important in the assembly of 
focal adhesion contacts during cell migration [82,83], and as a buffer for protons to support the 
catalytic activity of the enzyme [84]. Recent studies have also suggested that this PG domain may 
serve as a proton antenna for monocarboxylate transporters, to facilitate proton-coupled lactate flux 
[85]. 
The regulation of CAIX expression has been linked not only to the hypoxic tumour 
microenvironment, but also to genetic mutations, and dysregulated growth factor signalling 
pathways. In hypoxia, CAIX expression is mainly upregulated by the stabilization of the hypoxia 
inducible transcription factors (HIF) and the activation of the HIF signalling pathway. The HIF 
signalling pathway has been extensively reviewed elsewhere [86,87]. Briefly, HIF-1 is a heterodimeric 
transcription factor that is composed of an O2-regulated HIF-1α subunit and a constitutively 
expressed HIF-β subunit [88]. In the presence of oxygen, the tumour suppressor von Hippel–Lindau 
(pVHL) protein targets HIF-1α for proteasomal degradation by means of proline hydroxylation using 
O2 and α-ketoglutarate as substrates [89]. Most notable amongst the HIF target genes are the vascular 
endothelial growth factor (VEGF) [90], carbonic anhydrase 9 (CA9) [68], and components of metabolic 
pathways such as lactate dehydrogenase-A (LDHA) [91] and glucose transporters (GLUT1) [92,93]. 
Of these, CA9, the gene encoding CAIX, is one of most responsive genes to hypoxia because the 
hypoxia response element (HRE) sequence of this gene is localized just upstream of the transcription 
initiation site [94]. Due to the tight regulation by HIF-1, CAIX is predominantly expressed in regions 
of chronic hypoxia within solid tumours [68]. 
Mutations and dysregulated signalling pathways in cancers have been mechanistically linked to 
the regulation of CAIX expression via hypoxia-independent activation of HIF. The most notable 
example would be the inactivation mutations of the von Hippel–Lindau tumour suppressor (VHL) 
gene which lead to the constitutive activation of HIF signalling and CAIX expression in clear cell 
renal cell cancers (ccRCCs) and the von Hippel–Lindau syndrome hemangioblastomas [95,96]. 
Besides this, HIF-1α expression and signalling are also regulated by major signal transduction 
pathways, including those that involve phosphatidylinositol 3-kinase (PI3K) [97] and extracellular 
signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) [98,99] and upstream 
tyrosine kinases such as SRC and RET [100,101]. Mutations in other tumour suppressor genes such 
as PTEN, PML and TSC activate HIF by promoting its translation [102–104]. Less common activators 
of HIF are mutations in the Krebs cycle enzymes, fumarate hydratase and succinate dehydrogenase 
Cancers 2020, 12, 1616 7 of 23 
 
[105–107], where the resulting increased levels of fumarate or succinate act as 2-oxoglutarate 
analogues to inhibit pVHL prolyl hydroxylation, thereby activating HIF signalling [108,109]. 
CAIX is expressed in a wide variety of solid tumours, including breast [110,111], colorectal [112], 
glioblastoma [113], lung [114], head and neck [115,116], and cervical cancers [117]; its expression is 
typically associated with poor disease prognosis [110–117]. The correlation between CAIX expression 
and poor prognosis can be mechanistically explained by CAIX protecting the cancer cell from 
intracellular acidosis, allowing rapid tumour growth, and creating extracellular acidosis, which 
promotes cancer cell migration and invasion. Both catalytic and non-catalytic CAIX-associated 
mechanisms allow cancer cells to progress along the invasion–metastasis cascade and thus to seed 
distant metastatic outgrowths [83,118–120]. 
CAIX expression has been shown to have an important role in the regulation and maintenance 
of cancer stem cells (CSCs), a small but distinct subpopulation of cancer cells within a solid tumour 
that are capable of regenerating the tumour. CSCs exhibit many of the properties of stem cells 
including clonogenicity, self-renewal, quiescence, and the ability to undergo epithelial-to-
mesenchymal transition (EMT) [121,122]. In addition, CSCs have been shown to preferentially 
survive within hypoxic niches [123,124]. In the first study to report a link between CAIX and cancer 
stem cells, Lock et al. demonstrated that CAIX expression is required for the enrichment and function 
of breast CSCs in hypoxia, and that CAIX is required for mTOR signalling under hypoxia [125]. 
Intriguingly, CAIX expression was found to regulate the expression of ‘stemness’ genes such as Snail 
and Notch, and genes involved in the EMT; additionally, the inhibition of CAIX by small-molecule 
inhibitors depleted CSCs from tumours in vivo, reducing tumour growth and metastasis in 
preclinical models of cancer [125]. Ledaki et al. showed that subpopulations of cancer cells with 
hypoxia-inducible CAIX expression are enriched with cells that show high self-renewal capacity and 
express cancer stem cell markers. They also showed that the differential induction of CAIX under 
hypoxia is due to epigenetic regulation which induces differences in chromatin structure [126]. While 
these studies suggest that CAIX may be an important therapeutic target for selectively depleting 
CSCs, it remains unknown whether the effect of CAIX in CSCs is mediated through its role as a 
regulator of tumour pHe. 
CAIX catalyses the reversible hydration of CO2 at its exofacial site on the cell surface membrane, 
thereby placing it in a central position to regulate tumour pHe, and indirectly, pHi (Figure 1). To study 
the effect of CAIX on pHe and pHi, Swietach et al. employed confocal imaging using fluorescent pH 
dyes on 3D spheroid models of RT112 renal cancer cells [127] and HCT116 colorectal cancer cells [45], 
both of which overexpress CAIX. CAIX overexpression intensified the core-to-periphery pHi and pHe 
gradients of the spheroids, rendering the pHi of cells at the core less acidic, but making the peripheral 
pHe more acidic [45,127]. By the computational modelling of the data from their spheroid studies, 
they showed that CAIX maintains a steep outward-directed CO2 gradient across the plasma 
membrane, accelerating the CO2 excretion, and that this results in extracellular acidification and a 
more alkaline pHi [45]. Mathematical modelling of this reaction in vivo suggested that the hydration 
of CO2 at the extracellular surface of the cell membrane also allows the parallel diffusion of CO2, 
HCO3− and H+ across the interstitial space into the nearest blood vessel [45]. CAIX was predicted to 
exert an effect on the pHi and pHe in poorly perfused but metabolically active tissues, with the 
extracellular CO2/HCO3− buffer system driven out of equilibrium [45]. The effect of CAIX on pHe will 
depend on the type of acid released across the cell membrane, and the greatest acidifying effect would 
be observed if the cell metabolized glucose completely to CO2 [45]. In contrast, the greatest 
alkalinizing effect would occur if all the glucose was metabolized into lactic acid, without any 
neutralisation of the lactic acid by the HCO3− to form lactate- and H+ [45]. 
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Figure 1. Carbonic anhydrase IX (CAIX) links tumour energy metabolism to its pH regulation. 1. The 
major by-product of oxidative energy metabolism, CO2 diffuses across the cell membrane lipid bilayer 
into the extracellular space, along its concentration gradient; 2. On the extracellular surface of the cell 
membrane, the exofacial catalytic domain of CAIX catalyses the hydration of CO2 to form H+ and 
HCO3−; 3. In parallel, lactate, the end-product of glycolysis, exits the cell through the monocarboxylate 
transporter at a rate that is influenced by the pH gradient across the cell membrane (pHi–pHe 
gradient). GLUT, glucose transporter; MCT, monocarboxylate transporter. 
Hypoxic cancer cells display CAIX on their extracellular membrane but also have intracellular 
carbonic anhydrases such as CAII. This would allow them to extrude the H+ that is formed by the 
dissociation of the lactic acid product of anaerobic glycolysis, by using a Jacobs–Stewart Cycle (Figure 
2) [128]. Bicarbonate, formed by the mechanism shown in Figure 1, is transported by the Na+/HCO3− 
cotransporter into the hypoxic cell, where, under catalysis by CAII, it binds to H+, forming CO2 and 
H2O. The CO2 then diffuses through the cell membrane into the extracellular space where CAIX on 
the extracellular surface catalyses its hydration to HCO3− and H+; thus, an equivalent amount of H+ 
that was originally in the hypoxic cell is now in the extracellular fluid. Excess CO2 from the cancer 
tissue will diffuse to host capillaries. 
 
Figure 2. A Jacobs–Stewart Cycle helps hypoxic cancer cells extrude H+ produced by anaerobic 
glycolysis. 1. CO2 diffuses from the cancer cell into the extracellular space; 2. CAIX on the extracellular 
surface of the hypoxic cancer cell catalyses the hydration of CO2 to form H+ and HCO3−; 3. The HCO3− 
enters the hypoxic cancer cell via the Na+/HCO3− cotransporter and binds H+ from lactic acid, catalysed 
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by CAII, thus forming CO2; 4. The CO2 diffuses from the hypoxic cancer cell into the extracellular 
space, along its concentration gradient; 5. On the extracellular surface of the hypoxic cancer cell, CAIX 
catalyses the hydration of the CO2 to form H+ and HCO3−. The HCO3- provides further substrate to 
repeat stage 3 of the cycle, and an equivalent amount of H+ that was originally inside the hypoxic 
cancer cell (ringed in red) is now in the extracellular fluid; 6. Accumulating CO2 diffuses to a capillary. 
GLUT, glucose transporter; MCT, monocarboxylate transporter; NBC, Na+/HCO3− cotransporter. 
6. Discovery of the Tumour Extracellular pH-Stat Mechanism 
Stubbs et al. previously proposed that the acidic tumour pHe reflects more than just the high 
acid output of the cancer cells, and postulated the existence of an extracellular pH homeostatic 
mechanism, a pHe-stat, that was subverted by the cancer cell to set the pHe at a constant level and 
curtail excessive pH loading [129]. While an acidic tumour pHe promotes tumour growth and 
invasion, the pHe cannot be allowed to fall too low, as over-acidification would cause cell necrosis. 
Hence, cancer cells must utilise this pHe-stat to maintain a microenvironment that is hostile to the 
surrounding normal tissues, yet favourable for their own survival. 
If pHe was indeed under homeostatic control, then it should not correlate with pHi, whereas in 
a model of H+ transport, in which the rate of the H+ efflux from the cells depends only on the proton 
concentration in the interstitial space, there should be a tendency for pHi and pHe to be correlated. 
Using 31P MRS and the extracellular pH probe 3-APP, Stubbs et al. measured pHi and pHe in a range 
of rodent tumour models (RIF-1 fibrosarcoma, H9681a hepatoma and GH3 prolactinoma), and found 
no correlation between the pHi and pHe values [129]. These findings supported the hypothesis that 
the acidic tumour pHe is not simply a function of tumour metabolism per se, but is maintained by a 
homeostatic mechanism—a cancer pHe-stat. 
Several in vitro studies have suggested that the biochemical and biophysical properties of CAIX 
make it suited to the role of pHe-stat. In 2009, Alterio et al. published the first x-ray crystal structure 
of the catalytic domain of CAIX and showed that the presence of the proteoglycan chain at the border 
of the active site of the enzyme lowered its pKa from 7.01 to 6.49, ensuring that the enzyme had better 
catalytic efficiency at the acidic pH values at which it operated [130]. Using 18O exchange between 
CO2 and H2O to measure the exofacial CAIX activity in MDA-MB-231 breast cancer cells by 
membrane inlet mass spectrometry, Li et al. reported the first detailed measurement of the catalytic 
properties of the enzyme in its native membrane environment [131]. They found that the rate constant 
for the catalytic hydration reaction was faster than for the dehydration at the physiological pH of 7.4 
[131]. At pH 6.8, the rate constants for hydration and dehydration were essentially equal, and at pH 
values lower than 6.8, the dehydration reaction was faster [131]. Mahon et al. reported that the 
catalytic domain of CAIX exhibits biochemical and biophysical properties that create low pH stability 
and activity [132]. Taken together, these findings suggest that the primary role of tumour CAIX is to 
utilize the interconversion of CO2 and HCO3− in order to stabilize the pHe around 6.8, thus 
maintaining an acidic pHe set-point of cancer cells in response to the proton load from cellular 
metabolism. Intriguingly, the measurement of CAIX activity in vitro in HCT116 cells showed that CA 
activity was markedly reduced by decreasing the pH over the pH range found in tumours, with a pK 
of 6.84 and a Hill cooperativity coefficient of 2. This Hill coefficient would tend to sharpen the change 
in enzyme activity with pHe, suggesting that CAIX may have been adapted to provide a pHe-stat 
mechanism whereby excess acid self-limits the build-up of extracellular acid [80]. 
In parallel, several investigators have sought to study the effect of CAIX expression on tumour 
pHe in xenograft models, using various magnetic resonance-based pHe measurement techniques. 
Chen et al. employed the chemical exchange saturation transfer (CEST)-based MRI pHe measurement 
technique, acidoCEST MRI, to measure tumour pHe in a range of lymphoma xenograft tumour 
models (Raji, Ramos and Granta 519 cell lines) with different levels of CAIX expression [133]. The 
average tumour pHe ranged between 6.78 and 6.86, but there was no statistically significant difference 
between the mean pHe values of the different models. They derived a xenograft acidity score from 
the percentage and magnitude of the acidity, and found a correlation between that score and the level 
of CAIX expression in the tumour models, measured by histopathological staining [133]. Despite the 
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positive correlation, it was not possible to draw any conclusion about causality between the levels of 
CAIX expression and the xenograft acidity score. 
Using hyperpolarized 13C magnetic resonance spectroscopy with [13C] bicarbonate (H13CO3−), 
Gallagher et al. measured the pHe of two colorectal tumour xenograft models expressing different 
levels of CAIX [27]. However, while they observed a lowering of pHe in the CAIX-overexpressing 
tumours, the measured tumour pHe values were alkaline, likely an overestimation error due to the 
incomplete equilibration of the hyperpolarized 13C label between the H13CO3− and 13CO2 pools on the 
timescale of the 13C MRS measurements. This problem arises because the accurate measurement of 
pHe using the hyperpolarized 13C bicarbonate technique is dependent on the tissue having high levels 
of carbonic anhydrase activity [27]. Using 13C MRS magnetization transfer to measure the rate of 
exchange of hyperpolarized 13C label between bicarbonate and CO2, Gallagher et al. were able to 
measure the enzymatic activity of carbonic anhydrase in their tumour models and observed that, 
paradoxically, the tumours overexpressing CAIX showed a lower enzyme activity compared to the 
controls [27]. The administration of bicarbonate in the drinking water of mice elevated tumour pHe 
and restored enzyme activity to control levels, suggesting that the enzymatic activity of CAIX exhibits 
pH dependence and can be inhibited at low pH levels, akin to a negative feedback mechanism [27]. 
This observation suggests the interesting proposition that CAIX expression may be increased in 
hypoxia to compensate for the decreased specific activity of the enzyme at the lower pHe. 
To study the regulatory effect of CAIX on the tumour pHe, Lee et al. employed a high-resolution 
in vivo pH-imaging technique that was independent of the enzymatic kinetics of CAIX. Using 1H 
MRSI with an extracellular pH 1H MRS probe, ISUCA, they performed high-resolution spatial 
mapping of pHe in colorectal tumour xenograft models expressing different levels of CAIX, and 
observed that CAIX-expressing tumours had a more acidic pHe than the control tumours [134]. 
Importantly, the expression of CAIX imposed an upper limit of tumour pHe at 6.93, consistent with 
the hypothesis that CAIX acts as a pH-stat to maintain the pHe at a more acidic level than the typical 
pHe of 7.35–7.45 [134]. Intriguingly, there was no difference in pHi values between the CAIX-
expressing and non-CAIX expressing tumours, as measured by 31 P MRS, suggesting that CAIX 
acidifies only the tumour pHe and not pHi [101]. This latter observation was concordant with the 
earlier proposal of Stubbs et al. [129] that if pHe was indeed under homeostatic control, then it should 
not correlate with pHi. Additionally, these CAIX-expressing tumours were found to have a higher 
level of lactate compared to the control tumours [134]. Calculations of the ratio of lactate on either 
side of the membrane from the mean pHi and pHe values of these tumours revealed that CAIX-
expressing tumours had markedly higher intracellular lactate than non-CAIX expressing control 
tumours [134]. Collectively, these findings suggest that CAIX acts as a pH-stat that maintains an 
acidic tumour pHe. 
7. Implications of an Extracellular pH-Stat for Cancer Progression 
It is now well established that the acidic tumour pHe phenotype is associated with aggressive 
behaviour of solid tumours. Thomlinson and Gray first reported that human tumours grew as cords 
around blood vessels, and that as a tumour grows and outstrips its blood supply, its central region 
becomes hypoxic, although the cells remain within the diffusion distance of glucose [135]. Hypoxia 
upregulates glycolysis through the activation of hypoxia-inducible factor-1 (HIF-1) which induces 
the expression of glycolytic enzymes (e.g., lactate dehydrogenase A) [136], proton-exporting active 
transporters, (e.g., monocarboxylate transporter 4 (MCT4) [137]), and carbonic anhydrase IX (CAIX) 
[68]. 
These adaptations, which enable cancer cells to survive hypoxia by maintaining their 
intracellular pH within the physiological range and thereby creating an acidic pHe, have also been 
found to promote their invasion into normal host tissue and metastasis into other organs. Setting pHe 
to a constant acidic condition may therefore be an evolutionary strategy used by cancer cells to create 
an environment that fosters tumour growth and invasion in response to microenvironmental 
selection forces. One could even argue that the characteristically hypoxic tumour microenvironment 
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and the chaotic blood supply that gives rise to it are both evolutionarily selected features that are 
driven by the aggressive phenotype conferred on cancer cells by extracellular acidity. 
Gatenby, Gillies and colleagues have shown that an acidic pHe promotes tumour local invasion 
and metastasis, and that cancer cells are able to modulate the set point of tumour pHe in response to 
microenvironmental selection pressures as an evolutionary strategy favouring invasion [21,138]. At 
the cellular level, migrating cancer cells have proton-exporting machinery, such as sodium–hydrogen 
exchangers (NHE1) or sodium-bicarbonate cotransporters (NBCn1), coupled to CAIX at the front of 
their invadopodia, resulting in a more acidic pHe at the leading edge of the migrating cell [83,119] 
which activates proteases, e.g., lysosomal cathepsins, that then degrade the host’s extracellular matrix 
[139,140]. Gatenby et al. initially reported in silico mathematical simulations predicting that tumours 
acidified the extracellular space of normal tissue around the tumour edge [141], and confirmed these 
predictions via the intravital imaging of PC3N and MCF7 tumours, grown in dorsal window 
chambers [21]. They measured the peritumoural H+ flow using vectors generated from pHe 
distribution around the tumours, and found a general flow of tumour-derived acid from the core to 
the periphery, and then into the surrounding normal tissue [21]. In another study using dorsal 
window chamber tumour models and the confocal imaging of pHe with a fluorescent pH indicator, 
SNARF-1 Free Acid, they observed that the acidic pHe of peritumoural tissues was coincident with 
the location of subsequent tumour invasion, confirming a specific prediction of the acid-mediated 
invasion hypothesis [22]. The treatment of the animals with sodium bicarbonate reduced the pH 
gradient and reduced the local invasion in these tumour models [22]. Using a theoretical framework 
from evolutionary dynamics, Gatenby and Gillies proposed that the metabolic properties of cancer 
cells and their consequent interstitial acidification provided an evolutionary advantage that promotes 
tumour cell proliferation at the expense of the surrounding normal cells [142]. 
Further support for the acid-mediated invasion hypothesis has come from histopathological 
data showing cells at the invading edge expressing significantly more CAIX than those in the core of 
the tumour. Using quantitative image analysis of histologic specimens from patients with breast 
cancers, Lloyd et al. found that the spatial distribution of CAIX was consistently higher in the invasive 
tumour edge compared to the centre in all samples, which matched the predictions of evolutionary 
game theory models [143]. A key assumption of their model was that CAIX was able to set the pHe 
at 6.8 and that it served as a biomarker of regional tumour acidity. Thus, cancer cells are predicted to 
evolve towards an evolutionarily stable state, dictated by their adaptations to changes in 
environmental conditions such as blood flow and hypoxia [143]. Collectively, these studies suggest 
that the acidic pHe confers a selective advantage during the somatic evolution of cancers by 
facilitating the invasion of cancer cells into surrounding normal tissues. 
8. CAIX as a Therapeutic Target in Oncology 
CAIX is a promising therapeutic target in oncology. In vivo studies have shown that the genetic 
ablation of CAIX reduced the growth rate of colon and breast cancer tumour xenografts. Using a 
tetracycline-inducible system for RNA-interference, Chiche et al. reported that silencing the ca9 gene 
reduced colorectal LS174Tr xenograft tumour volume by up to 40%, and that this also resulted in a 
compensatory upregulation of ca12 mRNA [78]. Consequently, the greatest reduction in tumour 
volume was achieved through silencing both ca9 and ca12 genes. In cultured cells challenged with a 
CO2 load, both CAIX and CAXII contribute to extracellular acidification and the maintenance of a 
more alkaline resting pHi [78]. In a 4T1 murine metastatic breast cancer model and an MDA-MB-231 
human breast xenograft model, Luo et al. reported that shRNA-mediated the silencing of CAIX-
attenuated tumour growth; it also inhibited spontaneous lung metastasis formation in the 4T1 model 
[78]. The effect on tumour growth and metastasis formation was recapitulated through the use of 
CAIX-specific small molecule inhibitors, confirming the efficacy of CAIX as a targetable biomarker 
for cancer therapeutics [78]. 
Another avenue for the use of CAIX inhibition may be as a combination therapy with 
antiangiogenic drugs; this could produce additive results, since immunohistochemical data show 
that CAIX is part of a resistance mechanism that enables tumours to adapt to the increased hypoxia 
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induced by bevacizumab treatment [80]. McIntyre et al. reported that the shRNA knockdown of CAIX 
in colon cancer HCT116 and U87 glioblastoma xenografts enhanced the effect of antiangiogenic 
therapy with bevacizumab, resulting in a reduced tumour growth rate in vivo [80]. They also used 
acetazolamide to inhibit the enzymatic activity of CAIX, which recapitulated the effects of a 
combination of CAIX knockdown and bevacizumab. Like Chiche et al., they found that CAIX 
knockdown induced the expression of CAXII in 3D spheroids, but not in 2D cell culture [80]. In 
spheroid culture and tumour xenografts, CAIX expression was found to increase the growth rate and 
the expression of Ki-67, a marker of proliferation, while at the same time promoting necrosis and 
apoptosis [80]. 
9. CAIX—Clinical Translation 
There is now convincing evidence that CAIX can serve as a biomarker and/or therapeutic target 
in various tumour types. To this end, a distinction can be drawn between the tumours that express 
CAIX as a consequence of inactivating mutations of the von Hippel–Lindau (pVHL) tumour 
suppressor protein, and tumours in which CAIX is present due to microenvironmental hypoxia. In 
the former group, exemplified by clear cell renal cell carcinoma (ccRCC), more than 90% of tumours 
with inactivating mutations of pVHL have a constitutive stabilization of HIF and a high percentage 
of tumour cells expressing CAIX [144,145]. In more advanced ccRCC, CAIX expression decreases due 
to a switch from the HIF-1 to the HIF-2 isoform, which explains why the low expression of CAIX 
(defined as staining fewer than 85% of cells) in such tumours is a marker of poor prognosis [146]. 
In many other tumour types, such as head and neck, breast, colorectal, brain and lung tumours, 
CAIX is expressed in areas that are hypoxic and/or acidic, and its expression usually increases with 
increasing tumour stage and grade [68]. Immunohistochemical staining of CAIX is mostly found at 
the plasma membrane, and while cytoplasmic and/or nuclear staining are also occasionally seen, their 
biological significance is unclear. In addition, CAIX expression is associated with various other 
prognostic variables including c-ErbB2/Her2 [147,148], EGFR [114,149], MMP-9 [149], CD44 [150] and 
Ki-67 [151]. CAIX can also be detected in tumour stroma, which is associated with poor prognosis 
[152]. As a consequence of ectodomain shedding and release in exosomes, CAIX can be detected in 
the body fluids of cancer patients, and this can be exploited for non-invasive screening or monitoring 
tumour response to therapy [153,154]. 
Patients with tumours highly expressing CAIX are at a higher risk of disease progression and 
metastasis, independent of the tumour type or site. In a meta-analysis of studies between 2001–2015 
involving more than 24,000 patients with non-RCC tumours, there was a strongly significant 
association between immunohistochemical CAIX staining and several different endpoints, including 
overall survival, disease-free survival, locoregional control, disease-specific survival, metastasis-free 
survival, and progression-free survival [155]. Besides this, numerous studies have reported the 
correlation between CAIX expression and resistance to chemotherapy [156], radiotherapy [115,157] 
and immunotherapies against PD-1 [158]. These findings provide a rationale for developing 
prognostic biomarkers and therapeutics based on CAIX expression. 
Inhibitors of carbonic anhydrase activity as emerging anticancer therapeutics have been 
reviewed elsewhere [159]. In general, therapeutic strategies targeting CAIX involve one of two 
approaches. The first is based on the role of CAIX in pH regulation and uses compounds that inhibit 
its enzymatic activity through binding at or near its active site. The efficacy of this approach has been 
demonstrated by several preclinical studies in murine models of cancer [78–80]. Recently, SLC-0111, 
a small molecule inhibitor of CAIX, successfully completed Phase I clinical trials for the treatment of 
advanced, metastatic solid tumours [160]. Efforts are also underway to recruit patients for a Phase 1b 
trial of SLC-0111 in combination with gemcitabine in metastatic pancreatic cancer [161]. However, 
the clinical use of single agent CAIX inhibitors is likely to be hindered by the cancer cell, inducing 
compensatory mechanisms such as the upregulation of CAXII expression, or other acid-extruding 
mechanisms such as NHE1, resulting in an unsatisfactory therapeutic effect. Therefore, a more 
prudent approach would be to explore the use of anti-CAIX therapy in conjunction with other 
established anti-cancer drugs. One example of this concept would be to use anti-CAIX therapy in 
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patients undergoing anti-VEGF therapy, since CAIX expression is upregulated as a compensatory 
mechanism in tumours experiencing hypoxia as a result of anti-angiogenesis [80,162]. Besides this, 
CAIX inhibition can also be used in conjunction with radiotherapy, which has been demonstrated by 
the use of DH348, a nitroimidazole-based anti-CAIX inhibitor that not only reduced tumour growth 
in mice but also sensitized the tumours to radiotherapy [163]. 
The second strategy targets CAIX by immunotherapy and exploits the tumour-associated 
expression pattern of CAIX. The use of monoclonal antibodies against CAIX ensures high specificity 
and selectivity that are superior to the effects of chemical inhibitors, and the quick cell-killing effect 
of antibody-dependent cellular cytotoxicity (ADCC) circumvents the development of compensatory 
mechanisms. Most of the studies using this strategy have been undertaken in animal models of RCC 
and in patients with non-metastatic RCC, using the chimeric human-mouse monoclonal antibody 
G250 (RENCAREX/GIRENTUXIMAB), which is a safe, well tolerated antibody that was found to 
prolong disease-free survival by up to 22 months in a subgroup of ccRCC patients with high tumour 
CAIX expression [164]. 
In non-RCC tumours, CAIX expression is less frequent and more heterogeneous, thus it may not 
be such an attractive target for immunotherapy. However, the association between CAIX and 
metastasis makes it a plausible target as an adjuvant for metastasis-targeted immunotherapy. Since 
tumour cells residing in hypoxic and acidic regions are associated with therapy resistance, it is 
conceivable that these cells will express CAIX and that they will survive chemotherapy and/or 
radiotherapy and seed metastatic outgrowths. While targeting CAIX in such cells is certainly an 
intriguing prospect, there are only a few reported studies on the detection of CAIX in metastatic 
lesions [165–167], therefore more evidence is needed to support this hypothesis. 
Our understanding of the function of CAIX in tumour pHe regulation has highlighted the 
importance of mitochondrial energy metabolism in cancer. In parallel, several studies have suggested 
that mitochondrial metabolism plays an important role in the development of drug resistance in 
cancer [168,169]. It has been argued that resistant cancer cells are more dependent on mitochondrial 
oxidative metabolism than glycolysis. In many haematological and solid tumours, treatment 
resistance is associated with a shift towards an oxidative phosphorylation-dependent energetic status 
[60,170–172]. Resistant cells display higher levels of reactive oxygen species (ROS) and increased 
mitochondrial mass, oxygen consumption, ATP production and fatty acid synthesis [173–175]. This 
metabolic adaptation has been hypothesized as a strategy to meet the increased energetic demands 
of DNA repair, drug efflux and detoxification. Furthermore, the inhibition of oxidative 
phosphorylation has been shown to abrogate resistance to EGFR inhibitors in EGFR-driven lung 
cancers [176], docetaxel in prostate cancer [177], MAPK inhibitors in melanoma [178] and 5-
fluorouracil (5FU) in colon cancers [179]. Therefore, combining conventional chemotherapies with 
mitochondrial inhibitors (e.g., metformin, tigecycline) represents a promising strategy [180]. In the 
context of CAIX and tumour pHe regulation, it is tempting to speculate that the inhibition of 
mitochondrial respiration may reduce the acidifying effect of CAIX on pHe. 
10. Conclusions 
Our understanding of tumour pH and its regulation has come a long way, since the landmark 
discoveries of cancer cell metabolism by Otto Warburg, and the first in vivo measurements of tumour 
intracellular and extracellular pH in solid tumours. The progress in recent decades in the fields of 
cancer modelling, molecular biology, genetics, and in vivo imaging techniques has provided us with 
a molecular-level understanding of acid-base homeostasis in cancer. Since its discovery in the early 
1990s, CAIX has emerged as an important pH regulator in solid tumours, with recent evidence 
demonstrating that it functions as a pHe-stat. With increasing knowledge about the contribution of 
acidic pHe to all steps of cancer development and progression, it is now evident that CAIX provides 
a selective advantage to cancer cells by allowing them to create a hostile acidic environment in which 
they can survive and thrive, but in which host cells cannot, and to acquire an invasive and metastatic 
phenotype. The fact that CAIX-expressing cancer cells generally represent the most aggressive 
fraction of solid tumours indicates a fertile avenue for clinical translation in terms of diagnosis, 
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prognosis, and therapy. It is unlikely, however, that targeting CAIX on its own will be sufficient to 
produce a meaningful clinical benefit because of the phenotypic plasticity and redundancies in 
cellular pH regulatory mechanisms. Probably, therefore, the greatest benefit of agents targeting CAIX 
would be realized by using them in combination with other therapeutic agents in an adjuvant or 
neoadjuvant setting. 
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